Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

被引:324
|
作者
Eich, Hans Theodor
Diehl, Volker
Goergen, Helen
Pabst, Thomas
Markova, Jana
Debus, Juergen
Ho, Anthony
Doerken, Bernd
Rank, Andreas
Grosu, Anca-Ligia
Wiegel, Thomas
Karstens, Johann Hinrich
Greil, Richard
Willich, Normann
Schmidberger, Heinz
Doehner, Hartmut
Borchmann, Peter
Mueller-Hermelink, Hans-Konrad
Mueller, Rolf-Peter
Engert, Andreas [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
关键词
POSITRON-EMISSION-TOMOGRAPHY; INTERNATIONAL PROGNOSTIC SCORE; NODE RADIOTHERAPY; STAGE-I; DISEASE; CYCLES; PROGRESSION; RADIATION; SUPERIOR; THERAPY;
D O I
10.1200/JCO.2010.29.8018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied. Patients and Methods Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 x 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT. Results With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%. BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%). However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%). Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%). Treatment-related toxicity occurred more often in the arms with more intensive therapy. Conclusion Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL. Four cycles of ABVD should be followed by 30 Gy of IFRT.
引用
收藏
页码:4199 / 4206
页数:8
相关论文
共 50 条
  • [31] Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial
    Gillessen, S.
    Pluetschow, A.
    Fuchs, M.
    Markova, J.
    Greil, R.
    Topp, M.
    Meissner, J.
    Zijlstra, J.
    Eichenauer, D.
    Broeckelmann, P.
    Diehl, V.
    Borchmann, P.
    Engert, A.
    von Tresckow, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 88 - 89
  • [32] Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma -: A comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group
    Eich, HT
    Haverkamp, U
    Engert, A
    Kocher, M
    Skripnitchenko, R
    Brillant, C
    Sehlen, S
    Dühmke, E
    Diehl, V
    Müller, RP
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03): : 860 - 865
  • [33] From involved-field to involved-node - Results of the Quality Analysis of the radiotherapy Reference Panel of the German Hodgkin Study Group as a part of HD17 Study
    Oertel, M.
    Hering, D.
    Kittel, C.
    Nacke, N.
    Kroeger, K.
    Kriz, J.
    Fuchs, M.
    Baues, C.
    Vordermark, D.
    Engenhart-Cabillic, R.
    Herfarth, K.
    Lukas, P.
    Schmidberger, H.
    Marnitz-Schulze, S.
    Borchmann, P.
    Haverkamp, U.
    Engert, A.
    Eich, H. T.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S34 - S34
  • [34] High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin's lymphoma
    Magagnoli, M.
    Balzarotti, M.
    Spina, M.
    Siracusano, L. V.
    Isa, L.
    Navarria, P.
    Morenghi, E.
    Tirelli, U.
    Santoro, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 53 - 53
  • [35] BEACOPP chemotherapy in elderly patients with advanced Hodgkin's disease: Analysis of the randomized trial HD9 for elderly patients of the German Hodgkin lymphoma study group (GHSG).
    Ballova, V
    Franklin, J
    Josting, A
    Wolf, J
    Diehl, V
    Engert, A
    BLOOD, 2003, 102 (11) : 400A - 400A
  • [36] Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
    Broeckelmann, Paul J.
    Buehnen, Ina
    Meissner, Julia
    Trautmann-Grill, Karolin
    Herhaus, Peter
    Halbsguth, Teresa V.
    Schaub, Valdete
    Kerkhoff, Andrea
    Mathas, Stephan
    Bormann, Matthias
    Dickhut, Andreas
    Kaul, Helen
    Fuchs, Michael
    Kobe, Carsten
    Baues, Christian
    Borchmann, Peter
    Engert, Andreas
    von Tresckow, Bastian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1193 - +
  • [37] Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma:: A retrospective analysis from the German Hodgkin Lymphoma Study Group
    Josting, A
    Nogová, L
    Franklin, J
    Glossmann, JP
    Eich, HT
    Sieber, M
    Schober, T
    Boettcher, HD
    Schulz, U
    Müller, RP
    Diehl, V
    Engert, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) : 1522 - 1529
  • [38] Biophysical analysis of acute toxicity of radiotherapy in Hodgkin's lymphoma - A comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group (GHSG)
    Eich, H
    Haverkamp, U
    Engert, A
    Kocher, M
    Skripnitchenko, R
    Sehlen, S
    Duehmke, E
    Diehl, V
    Mueller, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S219 - S219
  • [39] Quality control of involved-field radiotherapy in patients with advanced stage Hodgkin's lymphoma (HL) enrolled on the EORTC trial 20884
    Aleman, BMP
    Girinsky, T
    Strijk, S
    Van der Maazen, RWM
    Bortolus, R
    Meijnders, P
    Pinna, A
    Henry-Amar, M
    Raemaekers, JMM
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S205 - S206
  • [40] Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
    Rosenbrock, Johannes
    Kaul, Helen
    Oertel, Michael
    Celik, Eren
    Linde, Philipp
    Fan, Jiaqi
    Eichenauer, Dennis A.
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Kobe, Carsten
    Dietlein, Markus
    Fuchs, Michael
    Borchmann, Peter
    Eich, Hans Theodor
    Baues, Christian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1344 - 1352